Thyrocare Tech.

how big is Thyrocare Tech.?

As of Jun 06, Thyrocare Technologies Ltd has a market capitalization of 5,048.42 Cr, with recent net sales of 687.35 Cr and a net profit of 91.65 Cr over the latest four quarters. Shareholder's funds are 526.77 Cr, and total assets amount to 629.06 Cr as of Mar'24.

Market Cap: As of Jun 06, Thyrocare Technologies Ltd has a market capitalization of 5,048.42 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, the sum of Net Sales is 687.35 Cr, and the sum of Net Profit is 91.65 Cr. This data is presented on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is also on a Consolidated basis for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 526.77 Cr, while Total Assets amount to 629.06 Cr.

Who are in the management team of Thyrocare Tech.?

As of March 2022, the management team of Thyrocare Tech includes Rahul Guha (Managing Director & CEO), along with several independent and non-independent directors, such as Ramjee Dorai (Company Secretary) and Gopal Shivram Hegde. The team features a diverse mix of roles to oversee the company's operations.

As of March 2022, the management team of Thyrocare Tech includes the following individuals:<BR><BR>1. **Rahul Guha** - Managing Director & CEO<BR>2. **Ramjee Dorai** - Company Secretary & Compliance Officer<BR>3. **Gopal Shivram Hegde** - Independent Director<BR>4. **Neetin Shivajirao Desai** - Independent Director<BR>5. **Vishwas Madhav Kulkarni** - Independent Director<BR>6. **Indumati Gopinathan** - Independent Director<BR>7. **Dhaval Shah** - Non-Executive & Non-Independent Director<BR>8. **Dharmil Sheth** - Non-Executive & Non-Independent Director<BR>9. **Hardik Dedhia** - Non-Executive & Non-Independent Director<BR>10. **Prapti Ishwar Gilada** - Independent Director<BR>11. **Harshil Jiten Vora** - Independent Director<BR><BR>This team comprises a mix of independent and non-independent directors, along with key executive roles.

Who are the peers of the Thyrocare Tech.?

Thyrocare Tech.'s peers include Syngene Intl., Dr Lal Pathlabs, and Krsnaa Diagnost., among others. In terms of management risk, growth, and capital structure, Thyrocare Tech. is rated as having good management risk and capital structure, with a 1-year return of 67.17%.

Peers: The peers of Thyrocare Tech. are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Suven Life Scie., Vimta Labs, Laxmi Dental, Krsnaa Diagnost., and Tarsons Products.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs and Laxmi Dental, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., and Thyrocare Tech. Average management risk is noted at Vimta Labs and Krsnaa Diagnost., and Below Average management risk is seen at Suven Life Scie. and Tarsons Products. Growth ratings show that Excellent growth is found at Vimta Labs, while Average growth is observed at Poly Medicure and Indegene, and Below Average growth is noted at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Thyrocare Tech., and Krsnaa Diagnost. The rest have Below Average growth. Excellent capital structure is present at Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Thyrocare Tech., and Krsnaa Diagnost., while Good capital structure is seen at Laxmi Dental, and Below Average capital structure is noted at Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Suven Life Scie. at 160.99%, while the lowest is Syngene Intl. at -3.51%. Thyrocare Tech.'s 1-year return of 67.17% is significantly higher than that of Syngene Intl. Additionally, Krsnaa Diagnost. and Tarsons Products have negative six-month returns.

Is Thyrocare Tech. overvalued or undervalued?

As of July 3, 2025, Thyrocare Technologies is considered very expensive and overvalued due to its high PE ratio of 59.09, Price to Book Value of 9.91, and EV to EBITDA of 27.57, despite a strong ROCE of 35.59% and a one-year stock return of 59.53%.

As of 3 July 2025, the valuation grade for Thyrocare Technologies has moved from expensive to very expensive, indicating a significant concern regarding its current pricing. The company is deemed overvalued based on its high PE ratio of 59.09, a Price to Book Value of 9.91, and an EV to EBITDA of 27.57. These ratios suggest that investors are paying a premium for the stock relative to its earnings and book value.<BR><BR>In comparison to its peers, Thyrocare's valuation appears excessive, especially when looking at Max Healthcare, which has a PE of 112.13, and Apollo Hospitals with a PE of 75.12. While Thyrocare's ROCE stands at a robust 35.59%, the high PEG ratio of 2.01 further emphasizes the overvaluation concern. Additionally, despite a strong one-year stock return of 59.53% compared to the Sensex's 4.07%, the elevated valuation metrics suggest that the stock may not sustain this growth, reinforcing the conclusion that Thyrocare Technologies is overvalued.

What does Thyrocare Tech. do?

Thyrocare Technologies Ltd provides affordable diagnostic services in the healthcare sector, with recent net sales of ₹1,872 Cr and a net profit of ₹217 Cr as of March 2025. The company has a market cap of ₹6,131 Cr and key metrics include a P/E ratio of 69.00 and a dividend yield of 1.54%.

Overview:<BR>Thyrocare Technologies Ltd operates in the healthcare services industry, providing quality diagnostic services at affordable costs.<BR><BR>History:<BR>The company was incorporated in January 2000 and continues to operate in the healthcare sector. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1,872 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 217 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 6,131 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 69.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 1.54% <BR>Debt-Equity: -0.31 <BR>Return on Equity: 16.76% <BR>Price to Book: 11.32 <BR><BR>Contact Details:<BR>Address: D-37/1 TTC Industrial Area, MIDC Turbhe Navi Mumbai Maharashtra : 400703 <BR>Tel: 91-22-27622762 <BR>Email: investor_relations@thyrocare.com <BR>Website: http://www.thyrocare.com

Who are the top shareholders of the Thyrocare Tech.?

The top shareholder of Thyrocare Technologies is Docon Technologies Private Limited, holding 71.06%. Other significant shareholders include Nippon Life India Trustee Ltd at 7.05%, mutual funds with 12.97%, foreign institutional investors at 2.41%, and individual investors with 9.21%.

The top shareholders of Thyrocare Technologies include a mix of promoters, mutual funds, and individual investors. The majority shareholder is Docon Technologies Private Limited, which holds a significant 71.06% of the company. Promoters collectively have pledged their holdings entirely. Among public shareholders, Nippon Life India Trustee Ltd, representing the Nippon India Small Cap Fund, is the largest with a holding of 7.05%. Additionally, mutual funds account for 12.97% of the shares, held by seven different schemes, while foreign institutional investors (FIIs) hold 2.41%. Individual investors collectively own 9.21% of the company.

Has Thyrocare Tech. declared dividend?

Yes, Thyrocare Technologies Ltd has declared a 70% dividend, amounting to ₹21 per share, with an ex-date of July 25, 2025. The company has demonstrated strong total returns across various periods, reflecting its commitment to shareholder value.

Thyrocare Technologies Ltd has declared a 70% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 70%<BR>- Amount per share: 21<BR>- Ex-date: Jul-25-2025<BR><BR>Dividend Yield: 1.69%.<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was 6.28%, the dividend return was 2.37%, resulting in a total return of 8.65%.<BR><BR>Over the past 6 months, the price return reached 79.35%, with a dividend return of 3.81%, culminating in a total return of 83.16%.<BR><BR>For the 1-year period, the price return was 43.61%, the dividend return was 3.11%, leading to a total return of 46.72%.<BR><BR>In the 2-year span, the price return stood at 123.52%, with a dividend return of 8.53%, resulting in a total return of 132.05%.<BR><BR>Over the last 3 years, the price return was 89.03%, the dividend return was 9.93%, giving a total return of 98.96%.<BR><BR>In the 4-year period, the price return was 11.77%, with a dividend return of 6.78%, resulting in a total return of 18.55%.<BR><BR>Finally, in the 5-year period, the price return was 25.73%, the dividend return was 9.86%, leading to a total return of 35.59%.<BR><BR>Overall, Thyrocare Technologies Ltd has shown a strong performance with significant total returns across various periods, supported by a declared dividend, indicating a commitment to returning value to shareholders.

How has been the historical performance of Thyrocare Tech.?

Thyrocare Tech. has shown steady growth in net sales and profits, with net sales increasing from 402.91 Cr in Mar'19 to 687.35 Cr in Mar'25, and profit after tax rising to 92.19 Cr in Mar'25. The company has demonstrated resilience with improved earnings per share and strong cash flow from operating activities.

Answer:<BR>The historical performance of Thyrocare Tech. shows a steady growth in net sales and profits over the years, with a notable increase in recent years.<BR><BR>Breakdown:<BR>Thyrocare Tech. has demonstrated a consistent upward trend in net sales, rising from 402.91 Cr in Mar'19 to 687.35 Cr in Mar'25. Total operating income followed a similar trajectory, reaching 687.35 Cr in Mar'25, up from 571.88 Cr in Mar'24. The company's total expenditure also increased, amounting to 496.99 Cr in Mar'25 compared to 434.45 Cr in Mar'24. Operating profit, however, saw fluctuations, peaking at 264.14 Cr in Mar'22 before declining to 205.19 Cr in Mar'25. Profit before tax increased to 146.88 Cr in Mar'25 from 95.59 Cr in Mar'24, while profit after tax rose to 92.19 Cr in Mar'25, up from 69.10 Cr in Mar'24. The earnings per share (EPS) improved to 17.27 in Mar'25 from 13.36 in Mar'24. On the balance sheet, total assets grew to 684.22 Cr in Mar'25 from 629.06 Cr in Mar'24, while total liabilities also increased to 684.22 Cr in Mar'25. Cash flow from operating activities showed a positive trend, reaching 191 Cr in Mar'25, indicating strong operational performance. Overall, Thyrocare Tech. has shown resilience and growth in its financial metrics over the years.

What is the bonus history of Thyrocare Tech.?

Thyrocare Technologies Ltd recently announced a 2:1 bonus issue, with an ex-date of November 28, 2025. Shareholders will receive two additional shares for every one share held as of that date.

Thyrocare Technologies Ltd has a recent bonus issue where they announced a 2:1 bonus. The ex-date for this bonus is set for November 28, 2025. This means that shareholders will receive two additional shares for every one share they hold as of the record date, which is also November 28, 2025. If you have any further questions about Thyrocare or its corporate actions, feel free to ask!

Is Thyrocare Tech. technically bullish or bearish?

As of December 2, 2025, Thyrocare Tech. shows a mildly bullish trend supported by bullish MACD and moving averages, but tempered by a mildly bearish KST and Dow Theory signals, indicating caution in the current market.

As of 2 December 2025, the technical trend for Thyrocare Tech. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on both weekly and monthly time frames, and daily moving averages indicating bullish momentum. However, the KST shows a mildly bearish signal on the weekly chart, which tempers the overall bullish outlook. Bollinger Bands are also indicating mildly bullish conditions on both weekly and monthly charts. The RSI shows no significant signals, and Dow Theory reflects a mildly bearish stance on the weekly chart with no trend on the monthly. Overall, while there are bullish indicators present, the mildly bearish signals suggest caution in the current market environment.

When is the next results date for Thyrocare Technologies Ltd?

The next results date for Thyrocare Technologies Ltd is 28 January 2026.

The next results date for Thyrocare Technologies Ltd is scheduled for 28 January 2026.

Should I buy, sell or hold Thyrocare Technologies Ltd?

Why is Thyrocare Technologies Ltd falling/rising?

As of 28-Jan, Thyrocare Technologies Ltd's stock price is rising to Rs 459.00, up 1.27%. This increase is driven by a recent positive trend, although it has underperformed its sector today and experienced a significant drop in delivery volume.

As of 28-Jan, Thyrocare Technologies Ltd's stock price is rising, currently at Rs 459.00, reflecting an increase of Rs 5.75 or 1.27%. This upward movement can be attributed to a few key factors. Firstly, the stock has been on a positive trend, gaining for the last two days and achieving a total return of 3.73% during this period. Additionally, it opened with a gain of 2.49% today, reaching an intraday high of Rs 464.55.<BR><BR>Despite this rise, it is important to note that the stock has underperformed its sector by 0.55% today, and the delivery volume has decreased significantly, falling by 47.34% compared to the 5-day average. However, the stock remains liquid enough for trading, indicating that there is still interest among investors. Overall, the recent gains in price, coupled with the stock's strong performance over the past year and three years, contribute to the current upward movement in Thyrocare Technologies Ltd's stock price.

Which are the latest news on Thyrocare Tech.?

Are Thyrocare Technologies Ltd latest results good or bad?

Thyrocare Technologies Ltd's latest Q3 FY26 results are strong, with a net profit of ₹47.99 crores (up 79.94% year-on-year) and revenue growth of 22.09% to ₹216.53 crores. The improved operating margin and strong return on equity indicate effective management and a positive outlook for future growth.

Thyrocare Technologies Ltd's latest results for Q3 FY26 can be considered quite good. The company reported a net profit of ₹47.99 crores, which reflects a remarkable year-on-year growth of 79.94%. Additionally, revenue grew by 22.09% year-on-year, reaching ₹216.53 crores, and showed a solid sequential growth of 12.17% compared to the previous quarter.<BR><BR>The operating margin also improved significantly, expanding to 32.95%, which is an increase of 573 basis points from the same quarter last year. This indicates effective cost management and improved operational efficiency. Furthermore, the return on equity (ROE) stands at a strong 23.91%, highlighting the company's ability to generate substantial profits relative to shareholder equity.<BR><BR>Overall, these results demonstrate Thyrocare's robust performance, driven by its successful expansion in the diagnostic services sector and effective management strategies. The company appears well-positioned for continued growth in the future.